Introduction
To ll-like receptors (TLRs) belongt ot he family of pattern recognition receptors and participate in immune surveillance by detecting pathogen-associatedm olecular patterns (PAMPs). [1, 2] Upon recognition of PAMPs, TLRs recruit adapter molecules and initiate aw ide range of reactions leadingt ob oth innate and adaptive immune responses. To ll-like receptor 4( TLR4) is expresseda tt he surfaceo fi nnate immune cells (e.g.,m acrophages, dendritic cells) and specifically recognizes bacterial endotoxins,f or example, lipopolysaccharide( LPS) or lipooligosaccharide (LOS), [3] the main molecular components of the outer leafleto ft he outer membrane of Gram-negative bacterial cell walls. Lipid A, the membrane-anchoring moiety of LPS, is the biologically active part of LPS and LOS. [4] The current view of the molecular mechanism of TLR4 activationb ye ndotoxins (LPS or LOS) is based on the serial interactions of increasing affinity of as ingle LPS molecule with LPS-binding proteins:l ipopolysaccharide-binding protein (LBP), clustero fd ifferentiation 14 (CD14) and finally with myeloid differentiation factor 2 (MD-2), [5] inducing the dimerizationo fT LR4 by forming the complex (TLR4-MD-2-lipid A) 2 that in turn triggers intracellular To ll/interleukin-1 receptor (TIR) domain interactions and myddosomea ssembly. [6] Myeloid differentiation primary response gene 88 (MyD88)-dependent intracellular signaling of the membrane complex (TLR4-MD-2-lipid A) 2 and/or,a fter itse ndosomei nternalization, TIR-domain-containing adapter-inducing interferon-b (TRIF)-dependent signaling, lead to the productiono f, respectively,i nflammatory cytokines and interferonb.L PS and LOSa re amphiphilic molecules with typically low sub-micromolar/nanomolar critical micelle concentration (CMC) values in an aqueousenvironment, and hence have atendency to aggregate in concentration ranges relevantf or biological responses.C MC values between 1.3 and 1.6 mm have been measured by fluorescencec orrelation microscopy for Escherichia coli LPS. [7] However,a sf or every amphiphile, monomersa re also presenti nad ynamic equilibrium depending on the actual This study examines the effect of co-administration of antimicrobial peptides and the synthetic glycolipid FP7, which is active in inhibiting inflammatory cytokinep roductionc aused by TLR4 activation and signaling.T he co-administration of two lipopolysaccharide (LPS)-neutralizing peptides (a cecropin Amelittin hybrid peptidea nd ah uman cathelicidin)e nhances by an order of magnitude the potencyo fF P7 in blockingt he TLR4 signal. Interestingly,t his is not an additional effect of LPS neutralization by peptides, because it also occurs if cells are stimulated by the plant lectin phytohemagglutinin,an on-LPS TLR4 agonist. Our data suggest ad ual mechanism of action for the peptides, not exclusively based on LPS binding and neutralization, but also on ad irect effect on the LPS-binding proteins of the TLR4 receptor complex. NMR experiments in solution show that peptidea ddition changes the aggregation state of FP7, promoting the formation of larger micelles. These results suggest ar elationshipb etween the aggregation stateo f lipid A-like ligandsa nd the type and intensity of the TLR4 response.
concentration. The issue of whether large or small aggregates, or monomers, are the biologically active units of endotoxins has been thoroughly debated in the literature. [8] [9] [10] The first steps of LPSr ecognition and binding by LBP,a lbumina nd CD14 are probablyi nfluenced by the size and 3D shape of LPS aggregates, whereas the formation of supramolecular complexes between single LPS molecules and receptors (CD14 and MD-2) is the basis of sensitive and selectivee ndotoxin molecular recognition by the (TLR4-MD-2-lipid A) 2 active complex. [5, 6, 11, 12] Modulation of the TLR4 signal by agonists and antagonists is an innovative approacht odeveloping either immunostimulating agents, for example, vaccine adjuvants, or therapeutics that target inflammatory pathologies due to excessive TLR4 activation by bacterial PAMPs and endogenous damage-associated molecular patterns (DAMPs). [13, 14] Twos trategies are usually adopted to interferew ith TLR4 activation and signaling with small molecules:1 )LPS-binding molecules that prevent the interaction of LPS with receptors, and 2) inhibition of activated (TLR4-MD-2-LPS) 2 complex formation by molecules directly competing with LPS for the binding to MD-2 andC D14 receptors. Whereas the first strategy is mainly used to block TLR4 stimulation by LPS in sepsis and septic shock, the second one could be, in principle, appliedt o block aw ider array of pathologies deriving from TLR4 activation by DAMPs.
In the first approach, positively charged antimicrobialp eptides (AMPs) are known to bind to and neutralize LPS and interact with endotoxin. [15] The prototypic AMP is polymyxinB, [16] ac ationic, small, cyclic lipopeptide.F urther examples are cecropins, [17] magainins, [18] proline-arginine-rich peptides, [19] tachyplesin, [20] defensins, [21] and others. [22] [23] [24] The structures of many of these peptides are known andi nclude turn/loop, helix or b-sheet motifs. Neutralization of LPS by AMPs involves a strong exothermic coulombic interaction between the two species, with ensuing fluidization of LPS acyl chains, and a drastic change in LPS aggregate type from cubic into multilamellar and an increase in aggregate sizes;t ogether these effects bring about the inhibition of the binding of LBP and other mammalian proteins to thee ndotoxin. [25] The second approach to block the LPS-TLR4 signal is based on molecules that directly competew ith LPS or other ligands for the binding of MD-2 and CD14 co-receptors. Several small molecules with potent TLR4 antagonist activity are known, such as synthetic phosphorylated disaccharides mimicking lipid A( Eisai's eritoran being the most famous), [26] synthetic monosaccharides, [27] [28] [29] or naturala nd synthetic compounds with structures unrelated to lipid A. [14] We recently synthesized FP7 (Figure 1 ), ad iphosphorylated glucosamine monosaccharideb earing two myristic (C 14 )c hains linked to the C-2 and C-3 positions, which was shown to be active as aT LR4 antagonist in cells and in animal models. [30] [31] [32] Similarly to disaccharide-based lipid Am imetics that block TLR4, such as eritoran, FP7 binds to MD-2 by inserting its fatty acid C 14 linear chains into the receptor's binding cavity. [30] We were interested in investigating whether cationic peptides that interact with anionic LPS aggregates could also interactw ith the anionic monosaccharide FP7 and thus modulate its TLR4 antagonist activity.T ot his end, we decidedt oc ombine FP7 with cecropin A-melittin (CA-M)h ybrids, ac lass of AMPs in which the cationic Nterminus of cecropin A( CA) is fused to the hydrophobic Nterminus of melittin (M;A MPs 1-5), and with LL-37, ah uman cathelicidin that possesses av ariety of activities including endotoxin neutralization (AMP 6). [33] [34] [35] Specifically,w e screened six synthetic CA-M hybrids (Table 1) , specifically CA(1-8)M(1-18) [36] (AMP 1), CA(1-7)M(2-9) [37] (AMP 2), [K 6 (Me 3 )]CA(1-7)M(2-9) [38] (AMP 3), N a -Oct-CA(1-7)M(2-9) [39] (AMP 4), CA(1-7)M(5-9) [37] (AMP 5), and LL-37 [40] (AMP 6), for their effects on TLR4 activation if added alone to cells or in combination with the TLR4 antagonist FP7.
Results and Discussion
AMPs potentiation of FP7 antagonist activity on LPS-TLR4 signaling in HEK-BluehTLR4 cells
The effect of FP7/AMP co-administration was initially investigated in HEK-Blueh TLR4 cells. These cells are HEK293 cells stably transfected with human TLR4, MD-2, and CD14 genes. In addition, these cells possess ar eporter gene encoding as ecreted embryonic alkaline phosphatase (SEAP), which is produced upon activation of NF-kB. LPS binding triggers in sequenceT LR4 dimerization, myddosome formation and NF-kB activation,l eading to SEAP productiona nd secretion. The activity of compound FP7 as TLR4 antagonist was confirmed,e x- Table 1 . Primarystructures of the peptides used in this study.
Entry
Common name Sequence Ref. . [30] Interestingly,A MPs administered alone did not show any antagonist effect on the same cell line at the concentrationr ange used ( Figure S1 in the Supporting Information). FP7 was than co-administered (1:1 stoichiometric ratio) with AMPs 1-6. In the concentrationr ange (0 to 10 mm)t ested, AMPs 2-5 weakly enhanced FP7 antagonist activity (co-administration IC 50 was around1 .1-1.5 mm,T able 2), whereas AMPs 1 and 6s howed as tronger effect (IC 50 0.56 and 0.18 mm,r espectively;F igure 2a nd Table 2 ). To exclude the possibility that the activity increase was due to ac ytotoxic effect, all co-administrationswere assessed by the MTT test, and showedn oo rv ery low toxicity up to the highest concentration tested (10 mm; Figure S2 ). CA(1-8)M(1-18) (AMP 1) and LL-37 (AMP 6) most efficiently improve the TLR4 antagonist activity of FP7 in HEKBlue hTLR4 cells.
We then tested the activity of AMPs 1-6 as TLR4 antagonists in HEK-Blue hTLR4 cells. Peptides showed no or weak activity in preventing LPS-triggeredT LR4 activation. AMP 1a nd AMP 6 showed IC 50 values of 21.9 and 23.1 mm,r espectively,w hereas AMPs 2-5 were found to be inactive in neutralizing the LPS stimulus.A nI C 50 value of approximately 0.3 mm has been reportedf or LL-37 (AMP 6) in limulus amebocyte lysate(LAL) and whole blood( WB) assays. [34] The discrepancy in the IC 50 values we determined from HEK-Blue hTLR4 cell experimentsa nd that previously reported using LAL or WB assays is about two orders of magnitude.T his can be explained by experimental differences, such as incubation times (30 min pre-incubation with peptidef or LAL and WB assays, no pre-incubation in our experiments).
LL-37 (AMP6 )p otentiation of FP7 antagonist activity in lectin-stimulated cells
Considering that severalA MPs are known to interact with high affinity with LPS to promotei ts neutralization, [33, 35, 41] we next investigated if the potentiation of FP7 antagonist activity by AMPs was due exclusively to an eutralizing effect on the endotoxin. If so, the additivee ffectw ould be lost by stimulating cells with aT LR4 agonist different from LPS. The phytohemagglutinin (PHA) lectins PHA-L and PHA-P induce TLR4-dependent NF-kBa ctivation in ad ose-dependent manner,w ith a lower potency than LPS. [42] In our test of the activity of PHA-P as aT LR4 agonist( Figure 3A) , we aimed to ensure that the TLR4 activity of the lectin was not due to LPSc ontamination, thus we treated cells with either PHA-P alone or in the presence of the LPS sequestrant polymyxin B, obtaining similara ctivation values ( Figure 3B ). Next we used PHA-P-stimulated HEK-Blueh TLR4 cells to evaluatet he antagonista ctivity of FP7 in the presenceo fL L-37 (AMP 6). As expected, treatment with FP7 inhibited TLR4 activation in ad ose-dependent manner, confirmingt hat the compound interferes with receptor-ligand recognition ( Figure 3C ). Interestingly,o nt he same PHA-P-activated cells the potentiation of FP7 antagonism by LL-37 co-administration was maintained( Figure 3C ), suggesting that the enhancement of FP7 activity is at least in part independent from aL PS-neutralizing effect.
LL-37 (AMP6 )p otentiation of FP7 antagonist activity in human peripheralb loodmononuclear cells
We investigated whether the capacity of the most potent peptide, LL-37 (AMP 6), to enhanceF P7 antagonist activity occurs also in human monocytes that naturallye xpress TLR4. For this purpose, human peripheral blood mononuclear cells (PBMCs) were isolatedf rom buffy coats, pre-incubated with increasing concentrations (0.1-10 mm)o fF P7 or FP7/AMP 6m ix and stimulated with LPS (100 ng mL
À1
)a fter 30 min. We evaluated the production of the NF-kB-dependentp ro-inflammatory cytokine interleukin-1b (IL-1b)a sareadoutf or TLR4 pathway activation.A se xpected, FP7 wasa ble to decrease the production of IL-1b in ad ose-dependentm anner,h alvingt he amount of cytokiner eleased if administered at ac oncentration of 5 mm. The addition of AMP 6t oF P7 produces am uch more powerful inhibitory response, inhibiting the production of interleukin at al ower dose of 1 mm (Figure 4 ).
NMR analysis of glycolipid-peptide interactions
The additive effect of AMP 6o nF P7 activity in lectin-stimulated cells suggestst hat ad irect interaction between peptides and glycolipid might have an effect on TLR4 antagonism. The peptide-glycolipid interaction was studied by NMR for AMP 1 and AMP 6, by analyzing the perturbationso bserved on characteristic NMR parameters (e.g.,c hemical shifts, line widths, and signal intensities) of either binding partner.T he titration of AMP 1a nd AMP 6w ith FP7 ( Figures S3 and S11, respectively) revealed the broadening of the peptideNMR resonance signals upon additionofFP7, mainly aclear perturbation of the signals of the lateral chains of the hydrophobic amino acids. The experimentallyo bserved reductions in intensity ( Figures S4 and  S12 ), due to specific line broadening of these signals, probably arise from the changes in the transverse relaxation times of these signals, ac lear indication of binding between these two AMPs and FP7. The diffusion-ordered spectroscopy (DOSY) spectra of AMP 1a nd AMP 6s howed as trikingly low diffusion coefficient, much different from its low/medium molecular . LL-37 (AMP 6) potentiation of FP7a ntagonist activity in human PBMCs.PBMCs isolated from buffy coats werepre-incubated with FP7 or FP7/AMP 6m ix for 30 min and then stimulatedw ith LPS (100 ng mL À1 ). IL-1b productionw as quantified after incubation overnight. Data representthe mean AE SEM (**P < 0.01, ***P < 0.001) of at least threeindependent experiments. Figures S5 and  S13 ). This experimental evidencew as also confirmed by using TEM negative staining analysis ( Figures S6 and S14) . Indeed, filament-like shapes were observedf or the peptides alone. Interestingly, the diffusion coefficient of the both AMPs remained unaltered in the presence of FP7 (Figures S5 and S13) . Thus, the interaction of FP7 with these two AMPs (in excess), does not show al arge effect on the average size of the AMP aggregates.
The process was also monitored by measuring the NMR signals of FP7 protons upon addition of AMP 1( Figure 5A -I) and AMP 6( Figure 5B-I) . In both cases, the dramatic reduction of the intensity of the NMR signals correspondingt oa liphatic moieties allowed us to conclude that the interaction with AMPs 1a nd 6i nvolved the lipid chains ( Figure 5A -I and B-I for AMP 1a nd AMP 6, respectively). Three alternative hypotheses could explain these data. The peptide could act as linker between different FP7 aggregates ( Figure S7 ) and/or deform the FP7 micelle (FigureS8). Alternatively,t he peptidec ould participate in the formation of large aggregates ( Figure S9 ), behaving as al arge molecule, as earlier described for MD-2. [30] This model is in agreement with the DOSY observations (Figures S5 and S13) described above. Indeed, the DOSY experiment of FP7 in the presence of AMPs ( Figure 5A -IIand B-II for AMP 1a nd AMP 6, respectively)s howed clear perturbations of the diffusion coefficient measured for FP7 alone. In the case of AMP 1, for substoichiometric ratios of the peptide( [AMP 1]/ [FP7] = 0.06), the decrease in the diffusion coefficiento fF P7 is evident( Ta ble 3). AMP 6c auses ad ecrease in the diffusion coefficient of FP7,a lthought he observed perturbation is smaller than that in the presence of AMP 1( Ta ble 3).
This effect could, in principle, be due to changes either in the size or shape ( Figures S7 and S8 ) of the lipid. Thus, we used TEM with negative staining analysis (Figures S10 and S14) and cryo-microscopy ( Figure 4A -III andB -III)t oo btain the required morphological information. It was possible to observe that the presence of AMP 1i nduced formation of aggregates between different FP7 micelles, thus supporting the change in size. The peptide is linking various FP7 micelles, displaying peanut-shaped structures.T his suggestst he presence of fusion events( indicated with the red circle in Figure 4A -III and Figure S10) . In contrast, the TEM analysiso fF P7 in the presence of AMP 6s howedadramaticc hange in the shapeo ft he micelles,f rom spheres to cylinders. Long entangled cylindrical micelles are displayed in the cryo-TEM image ( Figure 5B-III) and in the negative staining analysis (Figure S14, right) .
Conclusions
Compound FP7 has been rationally designed to be aM D-2 ligand and shown to inhibit TLR4 signal in cells in the low micromolar range. [30] The mechanism of action is based on direct competition with LPS for interacting witht he MD-2 binding pocket. [30] We recently observed that FP7 targets selectively TLR4 and not TLR2, and that it is able to block the TLR4 signal activated by microbial PAMPs and also by endogenousD AMPs such as HMGB1 protein. [32] The potent and selective TLR4 antagonist activity and its lack of toxicity make FP7 ag ood lead for therapeutic development against pathologies generated by PAMP-TLR4a nd DAMP-TLR4 signaling. There is ap ressing need for new antimicrobiald rugs that can neutralize bacterial products such as endotoxins. In some pathologies such as inflammatory bowel disease (IBD;C rohn'sd isease and ulcerative colitis), inflammation induces damage of the intestinal epithelium, which becomes more permeable to bacteria. [43] Witha view to studying the synergistic combination of TLR modulators with antibacterial drugs for these and other inflammatory and autoimmunep athologies, we examined the combination of ap otent TLR4 antagonist with various AMPs and shown that co-administration of FP7 with cationic AMPs potentiates the antagonist action of FP7 on cells expressingh TLR4 and murinec ells. Out of the six AMPs studied, AMP 1a nd AMP 6 present the most pronounced effect. As olution structuref or CA(1-8)M(1-18) (AMP 1) is not available. Nevertheless,asixresidue-shorter version,C A(1-8)M(1-12), in aqueous solution (in the presence of structure-inducing trifluoroethanol) [44] has been shown to adopt am ajor helical structure, with three and one helix turns in the melittin and cecropin Am oieties, respectively,s eparated by af lexible hinge (residues Gly-Ile-Gly). These features have been postulated to be required for membrane disruption against both prokaryotic and eukaryotic cells. On the other hand, ah igh quality structure of human cathelicidin LL-37 (AMP 6) in SDS micelles has been determined by NMR spectroscopy using a 13 C, 15 N-labeled version. [45] In the SDS micelles,t he peptide adopted ac urved amphipathic helixbend-helix motif spanning most of its length (residues 2-31), a pattern not unlike that of CA(1-8)M(1-12) discussed above. Severalm echanisms can underlie the potentiating action of AMPs. Ad irect neutralizing effect on LPSb yA MP interaction cannotc ompletely explain the result, which is still observed if cells are stimulated by the plant lectin PHA insteado fL PS. Three possible mechanisms are:1 )direct binding of AMPs to CD14 and/orM D-2 receptors, with concomitant LPS displacement;2 )the aggregations tate of FP7 is affected by AMPs; 3) an allosteric action of AMPs that stabilizes the inactive FP7-MD-2-TLR4 complex.
The amphiphilic glycolipid FP7 hasaCMC of approximately 9 mm, [30] the same order of magnitude as thatc alculated for E. coli LPS (between 1.3 and 1.6 mm). [7] In the concentration range of our cell experiments( 0.1-10 mm), FP7 is therefore in equilibrium between aggregate and monomeric species.
Both NMR spectroscopy and TEM experiments clearly show an effect of both AMP 1o rA MP 6o nt he FP7 aggregation state. NMR spectroscopy shows that addition of either AMP to FP7 causest he formation of larger aggregates,a sr evealed by the reduction in the intensities of signals corresponding to the FP7 aliphatic chain protons and the decreaseo ft he FP7 diffusion coefficient in DOSY.C ryo-TEMi mages support these data and clearly show that, upon peptidea ddition, FP7 micellar aggregates( at 500 mm concentration) undergo ac hange in size and 3D shape from spheres to rod-like cylinders. NMR experiments provideavaluable indication on the ability of these AMPs to affect FP7 aggregation state in an aqueous environment. However,b ecause they have been performed at ac oncentration two orders of magnitude highert han that at which FP7 is biologically active, they might suggestasimilar behavior of the peptides on FP7 under biological conditions but do not allow ad efinitive conclusion on this. Am ore detailed physicochemicalc haracterization of FP7-AMP co-aggregates is in progress.
In pathologies in which inflammation is exacerbated by bacterial infection, the combined use of anti-TLR (anti-inflammatory) small molecules with AMPs,a sd iscussed here for the TLR4 antagonist FP7 and peptides CA (1-8)M(1-18) and LL-37, might become av aluablea nd innovative therapeutic approach. Moreover, the capacity of AMP peptides to potentiate the TLR4 antagonist action also in the absence of LPS opens the way to new mechanisms of antagonism based on the direct binding of AMPs to MD-2 or formation of AMP-antagonist co-aggregates or allosteric modulation of TLR4 by AMPs.
Experimental Section

NMR spectroscopy
All NMR experiments were recorded on aB ruker Avance III 800 MHz spectrometer equipped with aT CI cryoprobe or aB ruker AvanceIII 600 MHz spectrometer equipped with aT BI probe. 
Transmission electronmicroscopy
All samples were prepared with in H 2 Oc ontaining 10 %D MSO. Samples for negative staining were applied to glow-discharged carbon-coated copper grids and stained with 2% (w/v)N anoVan (methylamine vanadate), Nanoprobes. Digital micrographs were taken at room temperature in low-dose radiation mode on aJ eol transmission electron microscope (JEM-1230) operated at 100 kV and equipped with an Orius SC1000 (4008 2672 pixels) cooled slow-scan CCD camera (GATAN, UK). For cryo-microscopy studies the samples were vitrified on Quantifoil 2/2 grids, using aV itrobot (FEI) and were analyzed at liquid nitrogen temperature with a transmission electron microscope operated at 200 kV in low-dose conditions. The samples were applied to glow-discharged carboncoated copper grids and stained with 2% (w/v)N anoVan. Micrographs were taken at al ow radiation dose on aJ EM-2200FS/CR transmission electron microscope (JEOL, Japan), equipped with an UltraScan 4000 SP (4008 4008 pixels) cooled slow-scan CCD camera (GATAN, UK).
Peptidesa nd biochemicals
Six AMPs were produced in high purity (> 95 %b ya nalytical HPLC) by Fmoc solid-phase synthesis methods, as reported (see Ta ble 1). The HPLC-purified materials had the expected composition as determined by electrospray or MALDI-TOFm ass spectrometry. E. coli LPS (O55:B5) and PHA-P lectin (from Phaseolus vulgaris)w ere supplied from Sigma-Aldrich. Polymyxin Bw as purchased from InvivoGen.
HEK-BluehTLR4 cell assay
HEK-Blue hTLR4 cells were purchased from InvivoGen and cultured according to the manufacturer's instructions in DMEM (Euroclone) supplemented with 10 %F BS, glutamine (2 mm), antibiotics (penicillin/streptomycin) and 1 HEK-Blue Selection (InvivoGen). Cells were detached from the plate using ac ell scraper,m ixed 1:1w ith trypan blue solution and counted. Cells were then diluted in complete DMEM with FBS (10 %) and glutamine (2 mm), plated in a9 6-well plate (3 10 4 cells per well) and incubated overnight (37 8C, 5% CO 2 ,9 5% humidity). Supernatants were removed and replaced with premixed DMEM without FBS (190 mLp er well) and test compound solution (different concentrations, 10 mLp er well). After 30 min cells were stimulated with LPS (100 ng mL À1 )a nd incubated for 16 h, as above. Supernatants were then collected and incubated with p-nitrophenyl phosphate solution (0.8 mm). Absorbance was monitored at 405 nm. All curves are representative of at least three independent experiments.
Human peripheral blood mononuclearcells
PBMCs were isolated by density gradient centrifugation (Lympholyte-H, Cedarlane Labs) from buffy coats. In brief, buffy coats were diluted 1:1w ith phosphate-buffered saline (PBS), and layered on Lympholyte-H for density gradient centrifugation according to the manufacturer's instructions. PBMCs were harvested from the interface and washed in PBS. The isolated cells were counted, checked for viability using 0.1 %t rypan blue and resuspended in RPMI 1640 supplemented with 10 %f etal bovine serum (FBS), penicillin (100 UmL À1 )a nd streptomycin (100 UmL
À1
). Cells were plated in 96-well U-bottomed multiwell culture plates (Euroclone), pre-incubated with increasing concentrations of FP7 and FP7/AMP 6m ix (0.1, 1, 5, 10 mm)a nd stimulated with smooth lipopolysaccharide (S-LPS; E. coli 055:B5;S igma;1 00 ng mL À1 )a fter 30 min. Each patient who took part in the study gave written informed consent, and the study protocol was approved by the local ethics committees (agreement between Ospedale Niguarda Cà Granda and Università degli Studi di Milano-Bicocca for the supply of buffy coats for research use).
MTT cell viability assay
HEK-Blue hTLR4 cells were seeded in a9 6-well multiwell plate at the density of 3 10 4 cells per well. After overnight incubation, the test compounds were added at different concentrations to each well and the plate was incubated for 16 h. PBS was included as an internal control. The supernatant of each well was then collected and replaced with of DMEM (90 mL) and MTT solution (5 mg mL À1 in PBS, 10 mL). The plate was incubated for 2-4 ha t3 78C, 5% CO 2 , 95 %h umidity.F ormazan crystals were dissolved by adding HCl in 2-propanol (0.1 n,1 00 mLp er well) and the absorbance was measured at 570 nm (LT-4000 Microplate Reader,L abtech). The results were normalized to untreated cells (PBS) and expressed as the mean percentage AE SEM of three independent experiments.
